株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

変性円盤疾患 : パイプライン製品の分析

Degenerative Disc Disease - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 257809
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.29円で換算しております。
Back to Top
変性円盤疾患 : パイプライン製品の分析 Degenerative Disc Disease - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 65 Pages
概要

変性円盤疾患は、脊柱の椎間板が変性するもので、その変性した椎間板が痛く、動作によっては悪化する場合があります。素因としては、加齢やけが、身体的外傷などによるもので、治療には非ステロイド性抗炎症薬や、筋弛緩薬、鎮痛剤、抗鬱剤などを用います。

当レポートでは、変性円盤疾患の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 変性円盤疾患 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • AnGes MG, Inc.
  • Asterias Biotherapeutics, Inc.
  • Biogenomics Limited
  • Biopharm GmbH
  • BioRestorative Therapies, Inc.
  • Bone Therapeutics SA
  • DiscGenics, Inc.
  • ISTO Technologies, Inc.
  • TissueGene, Inc.
  • Yuhan Corporation

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9010IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2017, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 1, 1, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Degenerative Disc Disease - Overview
  • Degenerative Disc Disease - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Degenerative Disc Disease - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Degenerative Disc Disease - Companies Involved in Therapeutics Development
    • AnGes MG Inc
    • Biogenomics Ltd
    • Biopharm GmbH
    • BioRestorative Therapies Inc
    • Bone Therapeutics SA
    • DiscGenics Inc
    • ISTO Technologies Inc
    • Osiris Therapeutics Inc
    • Samumed LLC
    • TissueGene Inc
    • U.S. Stem Cell Inc
    • Yuhan Corp
  • Degenerative Disc Disease - Drug Profiles
    • AdipoCell - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALLOB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-0103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BRTX-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dibotermin alfa biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NuQu - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OTICR-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Poly N-Acetyl Glucosamine Hydrogel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-04690 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Degenerative Disc Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Degenerative Disc Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-0002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-14618 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Degenerative Disc Disease - Dormant Projects
  • Degenerative Disc Disease - Product Development Milestones
    • Featured News & Press Releases
      • Feb 08, 2017: BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease
      • Jan 09, 2017: BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease
      • Nov 15, 2016: Samumed Presents Data for a Small Molecule Modulator of Wnt Pathway as a Potential Treatment for Degenerative Disc Disease
      • Nov 01, 2016: Samumed to present data on SM-04690 at American College of Rheumatology 2016 Annual Meeting
      • Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
      • Sep 12, 2016: BioRestorative Therapies Announces Publication in Medical Journal of Positive Results of Long-Term Safety and Feasibility Study Using Cell Therapy to Treat Patients with Degenerative Disc Disease
      • May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
      • Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the 'Clinical Applications of Stem Cells' Conference
      • Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
      • Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product
      • Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA
      • Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA
      • Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
      • Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies
      • Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB phase II trial in spine fusion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Degenerative Disc Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Degenerative Disc Disease - Pipeline by AnGes MG Inc, H1 2017
  • Degenerative Disc Disease - Pipeline by Biogenomics Ltd, H1 2017
  • Degenerative Disc Disease - Pipeline by Biopharm GmbH, H1 2017
  • Degenerative Disc Disease - Pipeline by BioRestorative Therapies Inc, H1 2017
  • Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1 2017
  • Degenerative Disc Disease - Pipeline by DiscGenics Inc, H1 2017
  • Degenerative Disc Disease - Pipeline by ISTO Technologies Inc, H1 2017
  • Degenerative Disc Disease - Pipeline by Osiris Therapeutics Inc, H1 2017
  • Degenerative Disc Disease - Pipeline by Samumed LLC, H1 2017
  • Degenerative Disc Disease - Pipeline by TissueGene Inc, H1 2017
  • Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, H1 2017
  • Degenerative Disc Disease - Pipeline by Yuhan Corp, H1 2017
  • Degenerative Disc Disease - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Degenerative Disc Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top